tbuckley/cabot-search huggingface dataset:
NEURITIS
Authors: STANLEY COBB
Journal: JAMA (1934)

Neuritis is common; it is easily recognized, yet few conditions are so often inadequately diagnosed. The trouble is not that the physician does not name the pathologic condition correctly but that he is too willing to be satisfied with the mere naming and thereat cease his investigations. It seems important, therefore, to summarize at this time the status of knowledge concerning the etiology of neuritis so that the cause in each case may be more correctly understood and the treatment more appropriate. During the last fifteen years epidemics of encephalomyelitis, the advancing knowledge of dietary deficiency, and new industrial poisons have all added valuable facts to aid in the understanding of neuritis. Many textbooks give excellent descriptions of the different types of neuritis, but the material is widely scattered under various headings. Of the monographic studies the best are probably by Ross and Bury<sup>1</sup>in 1893, by Harris<sup>2</sup>in
International Communication
Authors: Murray Kornfeld
Journal: JAMA (1970)

Sir Winston Churchill, in a speech delivered at Harvard University in 1943, said: "There is a need for a universal language and progress is being made with a simplified form of the English language." During the ensuing 27 years, American English, due to international travel, radio, television, and the printed word, has become the means of international communication. As defined in<i>The Reader's Digest Great Encyclopedic Dictionary</i>, American English is the English language as spoken in the United States, with especial reference to pronunciation and vocabulary. William Morris, of the Heritage Publishing Company, in a radio broadcast on Oct 26, 1969, stated that American English is now the accepted language for international communication and that the company's dictionary for overseas consumption reflects this trend. This has been particularly evident in medicine. To keep abreast of current developments in medical science, both undergraduate and postgraduate medical students have been studying American
Gaucher Disease
Authors: Tracy Hampton
Journal: JAMA (2007)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
CLL2007FMP, a Phase III Randomized Multicentric Trial of the French Cooperative Group On CLL and WM (FCGCLL/MW) and the “Groupe Ouest-Est D'etudes Des Leucémies Aigües Et Autres Maladies Du Sang” (GOELAMS): Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Yields a Significantly Better Response Than Fludarabine (F), Cyclophosphamide (C) and MabCampath (Cam) (FCCam) In Previously Untreated B-Chronic Lymphocytic Leukemia Patients as Evaluated by a Sensitive …
Authors: Letestu Remi, Stéphane Leprêtre, Arnoulet Christine, Baseggio Lucille, Campos Lydia, Chatelain Bernard, Jacob marie-Christine, Legac Eric, Legarff-Tavernier Magali, Ticchioni Michel, Robillard Nelly, Delepine Roselyne, Levy Vincent, Katsahian Sandrine, Varet Hugo, Leblond Veronique, Cymbalista Florence, Feugier Pierre
Journal: Blood (2010)
THE VENDER OF INTELLECTUAL NOSTRUMS
Journal: JAMA (2011)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Gene Therapy with Neurogenin 3 and Betacellulin Reverses Major Metabolic Problems in Insulin-Deficient Diabetic Mice
Authors: V. Yechoor, V. Liu, A. Paul, J. Lee, E. Buras, K. Ozer, S. Samson, L. Chan
Journal: Endocrine Reviews (2009)

Insulin deficiency in type 1 diabetes leads to disruptions in glucose, lipid, and ketone metabolism with resultant hyperglycemia, hyperlipidemia, and ketonemia. Exogenous insulin and hepatic insulin gene therapy cannot mimic the robust glucose-stimulated insulin secretion (GSIS) from native pancreatic islets. Gene therapy of streptozotocin-diabetic mice with neurogenin 3 (Ngn3) and betacellulin (Btc) leads to the induction of periportal oval cell-derived neo-islets that exhibit GSIS. We hence hypothesized that this gene therapy regimen may lead to a complete correction of the glucose and lipid metabolic abnormalities associated with insulin deficiency; we further hypothesized that the neo-islets formed in response to Ngn3-Btc gene delivery may display an ultrastructure and transcription profile similar to that of pancreatic islets. We injected streptozotocin-diabetic mice with helper-dependent adenoviral vectors carrying Ngn3 and Btc, which restored GSIS and reversed hyperglycemia in these animals. The treatment also normalized hepatic glucose secretion and reversed ketonemia. Furthermore, it restored hepatic glycogen content and reinstated hepatic lipogenesis-related gene transcripts back to nondiabetic levels. By transmission electron microscopy, the neo-islets displayed electron-dense granules that were similar in appearance to those in pancreatic islets. Finally, using RNA obtained by laser capture microdissection of the periportal neo-islets and normal pancreatic islets, we found that the neo-islets and pancreatic islets exhibited a very similar transcription profile on microarray-based transcriptome analysis. Taken together, this indicates that Ngn3-Btc gene therapy corrects the underlying dysregulated glucose and lipid metabolism in insulin-deficient diabetic mice by inducing neo-islets in the liver that are similar to pancreatic islets in structure and gene expression profile.
Journal Irish Medical Association, Dublin
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Erratum to: Genetically-controlled Vesicle-Associated Membrane Protein 1 expression may contribute to Alzheimer’s pathophysiology and susceptibility
Authors: Daniel Sevlever, Fanggeng Zou, Li Ma, Sebastian Carrasquillo, Michael G. Crump, Oliver J. Culley, Talisha A. Hunter, Gina D. Bisceglio, Linda Younkin, Mariet Allen, Minerva M. Carrasquillo, Sigrid B. Sando, Jan O. Aasly, Dennis W. Dickson, Neill R. Graff-Radford, Ronald C. Petersen, Ferenc Deák, Olivia Belbin
Journal: Molecular Neurodegeneration (2015)

Following publication of this work, we noticed that we inadvertently failed to include Dr Ferenc Deák in the author list. The author list has now been corrected and the amended authors' contributions section has been modified accordingly below.
Antibody studies of factor VIII inhibitor in a case with Waldenström's macroglobulinemia
Authors: Takeshi Endo, Yutaka Yatomi, Norihiko Amemiya, Asako Mizoe, Masaki Iino, Hideyuki Ozawa, Shigemi Hosogaya, Yukio Ozaki
Journal: American Journal of Hematology (2000)

We report a case of Waldenström's macroglobulinemia with prominent bleeding tendency; laboratory investigation revealed an elevated activated partial thromboplastin time. Further laboratory evaluation showed circulating factor VIII anticoagulant, deemed polyclonal IgG, with a titer of 700 Bethesda Units/ml. The factor VIII inactivation kinetics of the patient plasma were identical to those of a type II inhibitor, and the inhibitor was found to recognize the A2 domain of the factor VIII heavy chain. Apparently, paraprotein is not always the cause of reduced activity of coagulation factors in neoplastic dysproteinemias. Am. J. Hematol. 63: 145–148, 2000. © 2000 Wiley-Liss, Inc.
Head Injuries: More Research Urged
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Sjogren's syndrome treated with bromhexine: a reassessment
Authors: L M Tapper-Jones, M J Aldred, D M Walker, A E Dolby, L Beck, R Hopkins, G Nuki
Journal: BMJ (1980)

radioactivity of the free amino-acid.At best this omission leaves the interpretation of the results in doubt; at worst it can lead to severely misleading conclusions.Our own studies, and those of others, have shown that protein synthesis in skeletal muscle, which contributes 25-50% of total body synthesis in man,' is acutely sensitive to food absorption2 and to the concentration of amino-acids and insulin.3We do not dispute that the available methods for measuring whole-body protein turnover may not be ideal.Indeed, we have spent considerable time and effort in analysing possible sources of error and in comparing different approaches with 15N and 14C.4 5 The conclusion that amino-acids are retained in the body during food absorption can be made from simple nitrogen balance experiments and also from more sophisticated studies with L-4C-leucine.6The latter technique has also been used to show that rates of protein metabolism do not alter during the day and night if the food intake is maintained constant throughout.7 Dr Adam and Professor Oswald may argue that stored amino-acids are retained in the free amino-acid pool of the tissues, rather than as protein, but this appears to us to be highly unlikely.The total body pool of free leucine is quite small compared with the daily intake from dietary sources,8 and the period of measurement (12 hours) allows plenty of time for re-equilibration after a change of intake.In concluding that protein turnover is sensitive to food intake we have been par- ticularly concerned with validating methods and with verifying results by using several different techniques both in man and in animals.
Transcriptional regulation by the helix bundle peptide hormones: growth hormone, prolactin, and hematopoietic cytokines
Authors: N. D. Horseman
Journal: Endocrine Reviews (1994)

TODAY it is stylish to remark with fascination at the multiple overlapping functions of interleukins, colonystimulating factors, and a host of other "cytokines" that have been discovered in recent years. As a reminder that this is not really a new observation, the first HBP hormone to be purified was PRL (1), and it was recognized to have such a variety of biological actions that by 1963 there had been created a "vast and confusing literature" (2) replete with multiple names for the same hormone and arguments about how many hormones were responsible for each biological activity. The pleiotropy of PRL actions prompted Bern and Nicoll (3) to suggest in 1968 that it be renamed either "versatilin" or "omnipotin" (3), and by 1980 more than 200 actions of PRL had been documented in the various vertebrate classes (4). Redundancies between actions of PRL and GH were widely appreciated by the 1950s, and the similarities of human (h) PRL and hGH actions resulted in such controversies that many doubted the existence of separate human PRL and GHs until hPRL was definitively purified by Friesen's group in 1972 (5).
Radiation Therapy
Authors: A. Charkravarti, M. Wang, I. Robins, A. Guha, W. Curren, D. Brachman, C. Schultz, A. Choucair, M. Dolled-Filhart, J. Christiansen, M. Gustavson, A. Molinaro, P. Mischel, T. Lautenschlaeger, A. Dicker, M. Mehta, C. A. Phillips, S. Dhulibala, D. Hallahan, J. Jaboin, F. S. Cardinale, P. Dickey, I. Goodrich, J. Gorelick, R. Sinha, V. M. Dest, C. Chen, C. Olsen, W. Franklin, B. Kleinschmidt-DeMasters, B. D. Kavanagh, K. Lillehei, A. Waziri, D. Damek, L. E. Gaspar, M. C. Stauder, N. N. Laack, M. J. Link, B. E. Pollock, P. J. Schomberg, J. F. Fraser, S. C. Pannullo, J. Moliterno, W. Cobb, P. E. Stieg, S. Vinchon-Petit, D. Jarnet, S. Michalak, A. Lewis, J.-P. Benoit, P. Menei, G. Desmarais, B. Paquette, R. Bujold, D. Mathieu, D. Fortin, K. C. Cuneo, J. J. Vredenburgh, J. H. Sampson, D. A. Reardon, A. Desjardins, K. L. Peters, J. P. Kirkpatrick, P. N. Patel, R. Vyas, U. Suryanarayan, D. Bhavsar, M. Mehta, C. Hayhurst, E. Monsalves, M. Van Prooijen, C. Menard, G. Zadeh, C. Chung, K. Burrell, P. Lindsey, C. Menard, G. Zadeh, S. H. Burri, A. L. Asher, R. B. Kelly, P. Boltes, R. W. Fraser, F. A. Dilmanian, A. Rusek, N. R. Desnoyers, J. Y. Park, B. Dane, I. Dioszegi, S. D. Hurley, M. K. O'Banion, D. Tomasi, R. Wang, A. G. Meek, L. Sleire, J. Wang, J. Heggdal, P.-H. Pedersen, P. O. Enger, D. A. Clump, R. Srinivas, R. E. Wegner, D. E. Heron, S. A. Burton, A. H. Mintz, S. P. Howard, H. I. Robins, W. A. Tome, A. J. Paravati, D. E. Heron, P. A. Gardner, C. Snyderman, C. Ozhasoglu, A. Quinn, S. A. Burton, K. Seelman, K. Seelman, A. H. Mintz, J. H. Chang, Y. G. Park, M. J. Mehta, P. N. Patel, R. K. Vyas, D. C. Bhavsar, J. N. Guarnaschelli, L. Imwalle, J. Ying, C. McPherson, R. Warnick, J. Breneman, S. S. Khwaja, N. N. Laack, N. M. Wetjen, P. D. Brown, M. Siedow, U. Nestler, J. Perry, A. Huebner, A. Chakravarti, T. Lautenschlaeger, J. Glass, D. Andrews, M. Werner-Wasik, J. Evans, R. Lawrence, N. Martinez, G. Anuradha, M. David, M. Sara, L. Mark, B. Ricardo, J. Jeff, H. Juan, D. Kozono, P. Zinn, K. Ng, C. Chen, E. Melian, V. Prabhu, A. Sethi, K. Barton, D. Anderson, R. C. Rockne, M. Mrugala, J. Rockhill, K. R. Swanson
Journal: Neuro-Oncology (2010)
Treatment of Paget disease of bone (osteitis deformans). Results of a one-year study with sodium etidronate
Authors: M. R. Khairi
Journal: JAMA (1974)

A double-blind crossover study was performed in which 50 symptomatic patients with Paget disease were treated with sodium etidronate (EHDP) doses of 1, 2.5, 5, 10, or 20 mg/kg or were given placebo. After six months, the patients were reassigned to treatment with placebo or sodium etidronate, 5,10, or 20 mg/kg. Sodium etidronate in dosages of 5,10, or 20 mg/kg/day resulted in significant improvement in levels of serum alkaline phosphatase and urinary hydroxyproline, as well as clinical symptoms and bone scans. Bone scans and urinary determinations showed statistically greater improvement with sodium etidronate 20 mg/kg, in comparison to patients who received sodium etidronate 5 mg/kg for 12 months. After withdrawal of effective therapy, five of nine patients continued to have remission of their symptoms with placebo for an additional six months. (<i>JAMA</i>230:562-567, 1974)
Council on Pharmacy and Chemistry
Journal: JAMA (1946)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Lectures on the Experimental Investigation of the Action of Medicines
Authors: T. L. Brunton
Journal: BMJ (1871)

coin/orison2 Eftocts of Drugs on diferent Animals in different Doses.-Alode of deter-miniing the Exact Cautse of Sy'mptomis.-A/K;ode raisinog Blood-pressure.-A/odes of counstintg of thze heart.-Cautses of Quickened Pulse.-DirectStimulation the Symt5pathetic.-Stimulation of Cardiac Ganglia.-Paw alysis of the /gqus-roots anzd Fibres, and of its ends in the Heart.Ca of Sloz Pulse.-Irritation of Vagus-roots.-Mode of szupplyinzg tze Head and Body witht dift6erent kinds of Blood.-Indirect Irritation Vaglsroofs through the Blood-pressure: mode of lowering raisit.-ReflexIrritatioz of Vagus.roots.-Indirect Irritationt lthroughi the Respiration.-Irritation of Vaqgus-fibres.-IncreasedCondzucting Pozoer of Fires.-Stimtulationz of Vagus-ends.-Paralysis thze pathetic.-Paralysis ofthe Cardiac Ganglia.-Part ofthte Ganzglionic Apparatus Afected.-Nervous System in the Heart.-MotorGanglia.-Stimtlatig Ganzglia.-Inhibitory Ganglia.-ConznzectintgApparatus.-Action of Drugs on the Inhibitory Apparatus-Nicotia, Ahuscaria.-Antagonism of Atropia and Physostigma: bearinigofthzison Thzera- peutics.-Paralysis of Co-ordinatinzg Appa-atus.-ParalysisMutsczular Fibres of thze Heart.
Traditional Chinese Concepts of Mental Health
Authors: Li Zhi-Zhong
Journal: JAMA (1984)

AS A valuable contribution to the world's common treasure of healing art, traditional Chinese medicine has gained international recognition. But up to the present, not so much is known of traditional Chinese concepts, theories, and instructions on mental health. Is this possibly because of a relative meagerness of the latter in Chinese civilization compared with the former? On the contrary, a brief review of traditional Chinese culture would convince us of the amazing richness of precepts in Chinese classics on mental health. In the ancient book<i>The Great Learning</i>, it was stated that the human mind is unable to maintain its normality under distractions by fear, anger, worry, or fixed desires. And the normality of the mind was ever believed to be prerequisite to one's personal, familial, and social wellbeing. This basic principle gave rise to a great variety of relevant philosophical thoughts in the following generations and, like a
Effect of adenosine therapy at reperfusion on myocardial infarct size in dogs
Authors: R. S. Vander Heide, K. A. Reimer
Journal: Cardiovascular Research (1996)

The concept of lethal reperfusion injury in ischemic myocardium has been the subject of controversy. Adenosine administered during reperfusion has been reported to limit lethal reperfusion injury in several studies. On the contrary, it has been reported that cardioprotection may not be achieved with adenosine alone but may occur if adenosine is co-administered with lidocaine. Still other investigators have reported no beneficial effect of adenosine, given with or without lidocaine. If the positive reports are reproducible, they are important both because they provide evidence for the existence of reperfusion injury and establish a rationale for preventing it. Thus, the present study was done to determine if adenosine could limit lethal reperfusion injury in a canine model of regional myocardial ischemia and reperfusion, carefully controlled for baseline predictors of infarct size. Dogs (n = 37) of either sex were subjected to 90 min of coronary occlusion followed by 3 h of reperfusion. Two groups of dogs received adenosine (150 μg/kg/min) intravenously for 155 min starting 5 min prior to the reperfusion. One treated group received adenosine only and a second group received adenosine plus lidocaine (2 mg/kg). Control dogs received a saline infusion. After 3 h of reflow, hearts were excised and infarct size was measured and expressed as a percentage of the ischemic area at risk (AAR). To control for variation in infarct size due to variation in collateral blood flow (CBF), infarct size among groups was compared using ANCOVA, using CBF as the independent variable and infarct size as the dependent variable. Transmural collateral blood flow and AAR were not significantly different between any of the groups. Mean infarct size (adjusted by ANCOVA) in control dogs (n = 9) was 38.1 ± 5.3% of the AAR. Neither adenosine (n = 9) nor adenosine plus lidocaine (n = 7) significantly limited infarct size (35.6 ± 5.6% AAR and 38.1 ± 7.7% AAR, respectively; both P = NS). Intravenous adenosine therapy (150 μg/kg/min) during reperfusion, whether administered alone or in dogs previously treated with lidocaine, did not limit infarct size after 90 min of regional ischemia in canine myocardium.